Oct 22, 2024 04:05PM
Oct 22, 2024 04:05PM
Sep 30, 2024 08:01AM
Sep 30, 2024 08:00AM
Sep 5, 2024 08:43PM
Sep 5, 2024 08:08AM
Sep 5, 2024 08:00AM Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Aug 14, 2024 06:43AM
Aug 13, 2024 08:00AM
Jul 10, 2024 08:05AM
Jul 10, 2024 08:00AM
Jun 6, 2024 07:58AM
Jun 6, 2024 07:57AM
May 13, 2024 06:33AM Ocuphire (OCUP) PT Lowered to $18 at Canaccord Genuity
May 10, 2024 08:00AM
May 6, 2024 08:00AM
May 3, 2024 08:00AM
Apr 22, 2024 08:00AM
Apr 11, 2024 10:03AM
Mar 8, 2024 08:00AM
Feb 23, 2024 08:00AM Ocuphire Pharma to Present in the BIO CEO & Investor Conference
Feb 15, 2024 04:10PM
Feb 14, 2024 08:03AM
Feb 14, 2024 08:00AM
Feb 5, 2024 08:00AM
Jan 24, 2024 04:10PM
Jan 4, 2024 08:01AM
Jan 4, 2024 08:00AM Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) L
Nov 30, 2023 08:00AM
Nov 27, 2023 04:38PM
Nov 27, 2023 08:04AM
Nov 27, 2023 08:00AM
Nov 13, 2023 08:00AM
Nov 2, 2023 08:00AM
Nov 1, 2023 04:52PM Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 1, 2023 08:05AM
Nov 1, 2023 08:05AM
Oct 26, 2023 08:00AM
Oct 6, 2023 08:00AM
Sep 27, 2023 08:02AM
Sep 27, 2023 08:00AM
Sep 27, 2023 08:00AM Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agoni
Sep 11, 2023 09:41AM
Sep 7, 2023 09:00AM
Aug 28, 2023 08:00AM
Aug 11, 2023 08:00AM
Aug 8, 2023 08:00AM
Jul 26, 2023 08:00AM
Jul 10, 2023 05:19PM Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 27, 2023 08:04AM

322,245 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All